Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Comparison of M-TAPA and External Oblique Intercostal Block for Intraoperative Opioid Consumption in Laparoscopic Cholecystectomy (MTAPA-EOI)

20 september 2026 uppdaterad av: İsmet Uluhan, Ankara Etlik City Hospital

Comparison of M-TAPA and External Oblique Intercostal Plane Block on Intraoperative Analgesia and Opioid Consumption Guided by Skin Conductance Algesimeter in Laparoscopic Cholecystectomy

This prospective, randomized, interventional study compares the effects of modified thoracoabdominal nerve block through perichondrial approach (M-TAPA) and external oblique intercostal plane block (EOI) on intraoperative analgesia and opioid consumption in patients undergoing elective laparoscopic cholecystectomy.

Eighty patients are randomized into two groups: the M-TAPA group and the EOI group. All patients receive standardized general anesthesia. Intraoperative analgesia is guided using the Skin Conductance Algesimeter (SCA), which reflects sympathetic nervous system activity by measuring fluctuations in skin conductance. The SCA parameter "peaks per second (PPS)" is used to assess nociceptive responses, and remifentanil infusion is titrated according to SCA values.

Patients assigned to the M-TAPA group receive bilateral ultrasound-guided M-TAPA block, while patients assigned to the EOI group receive bilateral ultrasound-guided external oblique intercostal plane block. In both groups, 20 mL of 0.25% bupivacaine is administered on each side.

Perioperative analgesia is standardized. All patients receive intravenous dexketoprofen toward the end of surgery. During postoperative follow-up, intravenous paracetamol is administered as rescue analgesia when the numeric rating scale (NRS) pain score is 4 or higher.

The primary outcome is the time-weighted average intraoperative remifentanil infusion rate (µg/kg/min). Secondary outcomes include total intraoperative remifentanil consumption, intraoperative hemodynamic parameters, SCA measurements, postoperative pain scores, time to first rescue analgesic requirement, rescue analgesic consumption, postoperative nausea and vomiting, and perioperative complications.

The study aims to compare the opioid-sparing and analgesic effects of M-TAPA and EOI under objective nociception-guided intraoperative analgesia.

Studieöversikt

Detaljerad beskrivning

This prospective, randomized, interventional study compares modified thoracoabdominal nerve block through perichondrial approach (M-TAPA) and external oblique intercostal plane block (EOI) in patients undergoing elective laparoscopic cholecystectomy.

A total of 80 patients are randomized in a 1:1 ratio to either the M-TAPA group or the EOI group. Patients and postoperative outcome assessors are blinded to group allocation. The anesthesiologist performing the block is not blinded because of the nature of the procedures.

All patients receive standardized general anesthesia. Intraoperative analgesia is guided using the Skin Conductance Algesimeter (SCA), which reflects sympathetic activation through fluctuations in palmar skin conductance. The SCA-derived parameter "peaks per second (PPS)" is used as a real-time measure of nociceptive activity. Remifentanil is administered by continuous infusion and titrated according to SCA values to maintain the predefined target range.

Patients randomized to the M-TAPA group receive bilateral ultrasound-guided modified thoracoabdominal nerve block through perichondrial approach. Patients randomized to the EOI group receive bilateral ultrasound-guided external oblique intercostal plane block. In both groups, 20 mL of 0.25% bupivacaine is administered on each side.

Intraoperative data include heart rate, mean arterial pressure, SCA-derived PPS values, and remifentanil infusion rates. The primary outcome is the time-weighted average intraoperative remifentanil infusion rate (µg/kg/min). Secondary outcomes include total intraoperative remifentanil consumption, frequency of SCA values outside the predefined target range, postoperative pain intensity assessed using the numeric rating scale (NRS), time to first rescue analgesic requirement, rescue analgesic consumption during the first 24 postoperative hours, postoperative nausea and vomiting, and perioperative complications.

Perioperative analgesia is standardized in both groups. All patients receive intravenous dexketoprofen toward the end of surgery. During postoperative follow-up, intravenous paracetamol is administered as rescue analgesia when the NRS pain score is 4 or higher.

The study is designed to determine whether M-TAPA and EOI differ in their effects on intraoperative opioid requirements and postoperative analgesia when intraoperative nociception is objectively monitored using the Skin Conductance Algesimeter.

Studietyp

Interventionell

Inskrivning (Faktisk)

80

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Yenimahalle
      • Ankara, Yenimahalle, Turkiet (Türkiye)
        • Ankara etlik city hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 80 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Patients aged 18-80 years
  • ASA physical status I-III
  • Scheduled for elective laparoscopic cholecystectomy under general anesthesia
  • Ability to provide written informed consent

Exclusion Criteria:

  • Patient refusal
  • Known allergy to local anesthetics
  • Chronic opioid use or opioid dependence
  • Neurological or psychiatric disorders affecting pain perception
  • Use of medications affecting autonomic nervous system activity, such as beta-blockers
  • Infection at the injection site
  • Coagulopathy or anticoagulant therapy
  • Pregnancy

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Stödjande vård
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: M-TAPA Group

Patients assigned to this arm received bilateral modified thoracoabdominal nerve block through perichondrial approach (M-TAPA) for perioperative analgesia during laparoscopic cholecystectomy.

Patients received bilateral ultrasound-guided modified thoracoabdominal nerve block through perichondrial approach (M-TAPA). A total of 20 mL of 0.25% bupivacaine was administered on each side for perioperative analgesia during laparoscopic cholecystectomy.

Andra namn:
  • M-TAPA
Aktiv komparator: EOI Group

Patients assigned to this arm received bilateral external oblique intercostal plane block (EOIPB) for perioperative analgesia during laparoscopic cholecystectomy.

Patients received bilateral ultrasound-guided external oblique intercostal plane block (EOI). A total of 20 mL of 0.25% bupivacaine was administered on each side for perioperative analgesia during laparoscopic cholecystectomy.

Andra namn:
  • EOI

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Time-Weighted Mean Intraoperative Remifentanil Infusion Rate
Tidsram: Intraoperative period (from induction to end of surgery)

The time-weighted mean intraoperative remifentanil infusion rate will be calculated throughout the surgical period and expressed as micrograms per kilogram per minute (µg/kg/min) based on continuous infusion data.

Intraoperative period (from induction to end of surgery)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Postoperative Pain Scores Assessed by Numeric Rating Scale
Tidsram: 0, 2, 4, 6, 12, and 24 hours postoperatively

Postoperative pain intensity will be assessed using the Numeric Rating Scale (NRS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate worse pain. Assessments will be performed at rest and during movement.

0, 2, 4, 6, 12, and 24 hours postoperatively
Time to First Analgesic Requirement
Tidsram: Within 24 hours postoperatively

Time to First Analgesic Requirement

Within 24 hours postoperatively
Rescue Analgesic Consumption
Tidsram: First 24 hours postoperatively

Total amount of rescue analgesic (dexketoprofen) administered within the first 24 hours postoperatively.

First 24 hours postoperatively
Mean Arterial Pressure
Tidsram: Intraoperative period

Mean arterial pressure (MAP), expressed in mmHg, will be recorded intraoperatively and compared with baseline values.

Intraoperative period
Heart Rate
Tidsram: Intraoperative period

Heart rate, expressed as beats per minute, will be recorded intraoperatively and compared with baseline values.

Intraoperative period
Skin Conductance Algesimeter(SCA)
Tidsram: Intraoperative period

Skin Conductance Algesimeter (SCA) peaks per second (PPS) values recorded intraoperatively to assess nociceptive responses.

Intraoperative period
Postoperative Nausea and Vomiting (PONV)
Tidsram: First 24 hours postoperatively

Incidence of postoperative nausea and vomiting within the first 24 hours after surgery.

First 24 hours postoperatively

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

15 maj 2026

Primärt slutförande (Faktisk)

31 augusti 2026

Avslutad studie (Faktisk)

1 september 2026

Studieregistreringsdatum

Först inskickad

5 maj 2026

Först inskickad som uppfyllde QC-kriterierna

15 maj 2026

Första postat (Faktisk)

19 maj 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

23 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

20 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

Individual participant data will not be shared in accordance with institutional policies

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera